Cardio-oncology & otherCohort study
Real-world incidence of cancer therapy–related cardiac dysfunction in a large, diverse, and contemporary cohort
- retrospective cohort study
Authors' conclusion
CTRCD was common and occurred predominantly within the first year after therapy initiation, potentially reflecting both early susceptibility and more intensive early surveillance. Variation across drug classes highlights differing cardiotoxic risk profiles. These findings support risk prediction models and targeted surveillance strategies to reduce downstream HF risk.
Study context
- Population
- Adult Kaiser Permanente Northern California (KPNC) members diagnosed with malignant tumours between 2012 and 2022 who received anthracyclines, human epidermal growth factor receptor (HER2) inhibitors, immune checkpoint inhibitors (ICIs), or tyrosine kinase inhibitorspatients (mean age 62 ± 14 years, 64% women, 57% non-Hispanic White)
- Participants
- 26,646 participants
- Exposure
- Cumulative incidence rates were calculated overall and by drug class
Main finding
As reported in the abstract
Cumulative incidence of CTRCD (>10% decline in left ventricular ejection fraction to <53% or incident heart failure (HF) identified by natural language processing)
Overall cumulative incidence of cancer therapy-related cardiac dysfunction (CTRCD)
8.4% (95% confidence interval 7.7-9.1)
Observational data: associations, not effects.
Further findings
| Outcome | HER2 inhibitors | ICIs | anthracyclines | tyrosine kinase inhibitors |
|---|---|---|---|---|
| Cumulative incidence of CTRCD by drug class | 10.7% | 5.2% | Not reported in the abstract | Not reported in the abstract |
- Cumulative incidence of CTRCD by drug class: Incidence was highest with HER2 inhibitors and lowest with ICIs (P < .001)
Timing of CTRCD events
- Nearly half of all events occurred within the first year
Original publication
Real-world incidence of cancer therapy–related cardiac dysfunction in a large, diverse, and contemporary cohort. ESC Heart Fail. Published 30 April 2026. doi:10.1093/eschf/xvag113
Summarised from the published abstract; every number is checked against it